AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04319185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assistance to perform Peritoneal Dialysis (PD) at home
Description: The patient receives assistance of up to one visit per day for three months depending on the patient's needs, as assessed by the interdisciplinary team, the nephrologist, and the primary investigator or delegate.
Study NCT01495156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium treatment in combination with a SGA (Second Generation Antipsychotic)
Description: All patients will be treated with aripiprazole with a target dose of 10 mg/day and a max daily dose of 30 mg. If aripiprazole is ineffective or not tolerated, it will be tapered and risperidone treatment will be started. If patient had an adequate aripiprazole trial in the past as described above, risperidone will be the initial treatment. Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day and a max daily dose of 6mg.~Subjects in the lithium /adjunctive SGA group will be started at 900 mg/day lithium in thrice daily dosing. The lithium dose will be increased to 1200mg/day on day 4 if lithium has been well-tolerated and symptoms of mania remain, as determined by a phone assessment done by a blinded study physician. The target serum level of lithium will be 1.2 mEq/L (range 0.8 to 1.4 mEq/L).
Study NCT01495156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Adjunctive SGA treatment
Description: All patients will be treated with aripiprazole with a target dose of 10 mg/day and a max daily dose of 30 mg. If aripiprazole is ineffective or not tolerated, it will be tapered and risperidone treatment will be started. If patient had an adequate aripiprazole trial in the past as described above, risperidone will be the initial treatment. Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day and a max daily dose of 6mg.~Subjects in the placebo /adjunctive SGA group will receive placebo for the entire trial in addition to the adjunctive SGA.
Study NCT03246646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Telephone coaching was provided in a series of telephone based sessions with CSO participants
Study NCT03246646 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Coaching
Description: Telephone coaching was provided in a series of telephone based sessions with CSO participants
Study NCT02517437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suprascapular & axillary blocks
Description: After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots to achieve circumferential spread around the nerve.The axillary nerve block will be performed next in the posterior aspect of the operative arm. The neurovascular bundle encompassing the humeral artery, posterior circumflex artery, and axillary nerve is visualized in the lateral edge of the quadrangular space, deep to the deltoid muscle, inferior to the teres minor muscle, and superior to the triceps tendon. After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots after negative aspiration to achieve circumferential spread around the bundle.
Study NCT02517437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene block
Description: After sterile skin preparation with chlorhexidine and infiltration with 1 mL of 1% lidocaine, a 5 cm 22 G insulated needle is then inserted and local anesthetic solution (20 mL of 0.5% ropivacaine) will be injected in 5 mL aliquots after negative aspiration for blood to achieve spread posterior to or between the C5 and C6 nerve roots.
Study NCT01914068 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise in hospital
Study NCT04253496 — intervention group
Intervention type: OTHER
Intervention: Tumor samples and MRI
Description: We will use DNA and RNA tumor samples. We will not use germline or blood DNA. These data will be combined with their magnetic resonance imaging (MRI) at different times: at diagnosis, at the end of treatment and at the progression of the disease.
Study NCT02784353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perioperative rehabilitation program
Description: Perioperative rehabilitation program~* preoperative rehabilitation : 2 weeks prior to operation~* postoperative rehabilitation : 3 months after operation
Study NCT02784353 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: conventional perioperative management without rehabilitation program
Study NCT02327416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y peginterferon alfa-2b
Description: In arm 2 and 3, Y peginterferon alfa-2b is used for 96 weeks
Study NCT02327416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony stimulating factor
Description: In arm 3, Granulocyte-macrophage colony stimulating factor is used for 48 weeks intermittently
Study NCT02327416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir and or adefovir dipivoxil
Description: In arm 1, Entecavir and or adefovir dipivoxil are used for 96 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir and or adefovir dipivoxil are used for 48 weeks.
Study NCT02327416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir and or adefovir dipivoxil
Description: In arm 1, Entecavir and or adefovir dipivoxil are used for 96 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir and or adefovir dipivoxil are used for 48 weeks.
Study NCT00221546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Giving DHA-rich supplement
Description: Giving DHA-rich supplement to patients.
Study NCT00221546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Giving DHA-rich supplement
Description: Giving DHA-rich supplement to patients.
Study NCT03384186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan Modified Release Prototype 1
Description: Danicopan (400 milligrams \[mg\]) oral tablet.
Study NCT03384186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan Modified Release Prototype 2
Description: Danicopan (400 mg) oral tablet.
Study NCT03384186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan Modified Release Prototype 3
Description: Danicopan (800 mg) oral tablet.
Study NCT01871545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging is a radiation free non invasive technique using magnetic radiofrequency waves to image the body. In this study, the research team would like to investigate the possibility of providing functional information on aggressiveness, vascularity and oxygen uptake in liver cancer tumors.
Study NCT03326063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifetroban
Description: 4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD
Study NCT03326063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD
Study NCT04237181 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Filmarray PCR multiplex-PCT assay
Description: Filmarray PCR multiplex gastro intestinal panel on stools and serum PCT dosage
Study NCT06443333 — intervention group
Intervention type: OTHER
Intervention: Data collection and follow-up observation
Description: At the time of enrollment, the patient's biological samples are collected to obtain genetic information. Following enrollment, trained investigators carry out a 2-year follow-up observation through face-to-face, telephone call or online visits. During the follow-up, basic clinical information, laboratory tests, imaging examinations, neurophysiology, clinical classification, medication use, and scale assessments are collected.
Study NCT06443333 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Collect demographic and genetic information from healthy volunteers upon enrollment.
Study NCT01768910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: 2 measurements using functional magnetic resonance imaging in a 3T scanner
Study NCT01768910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bladder filling
Description: Repetitive retrograde bladder filling via transurethral catheter with different filling volumes using body warm saline during each of the fMRI measurements.
Study NCT01768910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bladder cooling
Description: Retrograde bladder filling via transurethral catheter with 4-8°C saline during each of the fMRI measurements.
Study NCT01768910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: additional post-treatment fMRI scan
Description: Should NNOAB or SCI patients receive a study independent OAB therapy by their treating physician after the 2nd fMRI scan, they will be invited for an additional third fMRI scan.
Study NCT00371540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home visit by community care coordinators
Description: Decrease in patient visits to the clinic from the standard of once per month to every 3 months with home visits monthly.
Study NCT04233710 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Robot Rehabilitation + tDCS
Description: Robotic therapy with Kinarm Exoskeleton Robot and 1 mA cathodal tDCS applied to contralesional M1 for 20 minutes.
Study NCT04233710 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Robotic Rehabilitation + sham tDCS
Description: Robotic therapy with Kinarm Exoskeleton Robot and sham tDCS.
Study NCT03340311 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: iHealth Wireless Smart Gluco- Monitoring System (BG5)
Description: Over the course of 8 weeks, participants collected serum glucose logs (SGL) for 4 weeks using usual care followed by SGL's log for 4 weeks using Bluetooth-enabled glucometers and the iGluco application.
Study NCT03807245 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS-NN/NN2 with Alhydrogel® 25
Description: GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
Study NCT03807245 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo GBS-NN/NN2 with Alhydrogel® 25
Description: GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
Study NCT03807245 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo GBS-NN/NN2 with Alhydrogel® 50
Description: GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
Study NCT03807245 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS-NN/NN2 with Alhydrogel® 50
Description: GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
Study NCT02293824 — intervention group
Intervention type: DRUG
Intervention: Caffeine
Description: Given per standard of care.
Study NCT00588523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide followed by high dose busulfan and thiotepa
Description: Temozolomide 200mg/m2 PO Days 1-5 recycled every 28 days Day minus -8 thiotepa 250 mg/m2 intravenously Day minus -7 thiotepa 250 mg/m2 intravenously Day minus -6 thiotepa 250 mg/m2 intravenously Day minus -5 busulfan 3.2 mg/kg intravenously over two hours Day minus -4 busulfan 3.2 mg/kg intravenously over two hours Day minus -3 busulfan 3.2 mg/kg intravenously over two hours Day minus -2 rest Day minus -1 rest Day 0 peripheral blood stem cell or bone marrow reinfusion
Study NCT04966039 — intervention group
Intervention type: OTHER
Intervention: No intervention.
Description: There was no intervention.
Study NCT01880151 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG
Description: EEG recorded during a resting condition and during an episodic memory task condition
Study NCT02948582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate Inhalation Solution12.5μg
Description: Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily
Study NCT02948582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate Inhalation Solution 50μg
Description: Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily
Study NCT02948582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate Inhalation Solution 100μg
Description: Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily
Study NCT02948582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate Inhalation Solution 200μg
Description: Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily
Study NCT02948582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate Inhalation Solution 400μg
Description: Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily
Study NCT02948582 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0.5mL
Description: Placebo 0.5mL via eFlow, once daily
Study NCT04483258 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sedation with sevoflurane insufflation
Description: Induction with %8sevoflurane after adequate sedation reducing %3
Study NCT04483258 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravenous sedation
Description: midazolam +ketamine + atropine
Study NCT00678288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously
Study NCT00678288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006) + Interferon
Description: Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously. IFN alpha-2a 3MIU FIW s.c., from Monday to Friday (total weekly dose 15 MIU) s.c., to start one week after commencing sorafenib.
Study NCT02967679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD1003
Study NCT02881411 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-soft tissue therapy
Description: Manual therapy for the muscles in the upper or lower limbs.
Study NCT02881411 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fibromyalgia coping skills programme
Description: Exercise, education programme
Study NCT02253095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Study NCT02253095 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Study NCT02253095 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple Micronutrient Supplement
Study NCT02253095 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03654118 — intervention group
Intervention type: OTHER
Intervention: Phone follow-up
Description: Through a short phone interview :~* Determination of a complication (Infection, capsulitis, recurrence)~* Determination of the Rowe score~* Determination of the Walch-Duplay score
Study NCT03072472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endocuff Vision
Description: The EndocuffTM (ARC Medical Design Ltd and Diagmed, UK) is a device (CE marked in UK) made of a soft plastic material with a unique dynamic shape. Endocuff Vision™ is placed snugly around the colonoscope tip prior to insertion. It does not project beyond the tip of the scope, providing an unrestricted view. It helps anchor the scope tip against the bowel wall to provide a stable platform of access. The soft, elastic projections are pushed back (recoiled) towards the scope shaft during insertion but evert during withdrawal to hold colon folds away from the field of view.
Study NCT01934907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washing of packed RBC by normal saline
Study NCT02925559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: The active treatment will include a 10 mg dose of dapagliflozin orally once a day.
Study NCT02925559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide MR
Description: As comparator, gliclazide MR will be administered at a dose of 120 mg orally once a day.
Study NCT06445465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [18F]MNI-1216
Description: \[18F\]MNI-1216 is an intravenously administered radioactive imaging agent being studied as a potential positron emitting radiopharmaceutical for in vivo imaging of α-synuclein deposits.
Study NCT03464513 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Multislice CT Angiography
Description: Multislice CT angiography (MSCTA) provides a relatively non-invasive and effective way of localising the source of bleeding, especially in patients with continuous bleeding.
Study NCT00730353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib malate
Description: Sunitinib malate 37.5 mg orally, daily
Study NCT00730353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 90 mg/m2 IV on days 1, 8 and 15.
Study NCT04295811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EsoGuard (lab assay)
Description: EsoGuard assay (LDT) will be used on cells collected using the EsoCheck (510K cleared esophageal cell collection device)
Study NCT04295811 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy
Description: Planned EGD to diagnose and/or treat disorders of esophagus, stomach, and small intestine. When abnormal tissues are noted, biopsies of the tissue are taken through the scope to diagnose tissue abnormalities.
Study NCT03475446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real anodal tDCS healthy elderly
Description: A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the group of healthy elderly.
Study NCT03475446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real tACS healthy elderly
Description: A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the group of healthy elderly.
Study NCT03475446 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham tES healthy elderly
Description: A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the group of healthy elderly.
Study NCT03475446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real anodal tDCS MCI
Description: A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the MCI group.
Study NCT03475446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real tACS MCI
Description: A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the MCI group.
Study NCT03475446 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham tES MCI
Description: A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the MCI group.
Study NCT03475446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real anodal tDCS AD
Description: A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the AD group.
Study NCT03475446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real tACS AD
Description: A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the AD group.
Study NCT03475446 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham tES AD
Description: A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the AD group.
Study NCT04257643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aquatic based exercise.
Description: exercise under water with the patient standing in a swimming pool, for 60 minswith water to the neck and then practice the arm exercise plus the diaphragmatic breathing exercise. The duration of the exercise programs was selected to be 60 minutes, 3 days per week for 8-week intervention
Study NCT04257643 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: land-based exercise.
Description: land-based exercise session for 60 minutes for 8 weeks in the form of warm-up, strengthening, and cooling down exercise.Land-based exercise program: Supervised program consisted of 60-min sessions, three times a week, over 8 weeks. The exercise program consisted of the first 10 minutes for warm-up exercise with a small softball, fit -ball, mobility and stretching exercise. Then 30-40 minutes for strength development with different materials and positions, that require more body control and increase joint motion. Then the last 10 minutes for cooling down for stretching exercise for the arm muscles \[14\]. Women were asked to exercise continuously for 60 mins, by performing the arm exercises by repeating the session, and were instructed to exercise at moderate intensity .
Study NCT04257643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: land-based exercise.
Description: land-based exercise session for 60 minutes for 8 weeks in the form of warm-up, strengthening, and cooling down exercise.Land-based exercise program: Supervised program consisted of 60-min sessions, three times a week, over 8 weeks. The exercise program consisted of the first 10 minutes for warm-up exercise with a small softball, fit -ball, mobility and stretching exercise. Then 30-40 minutes for strength development with different materials and positions, that require more body control and increase joint motion. Then the last 10 minutes for cooling down for stretching exercise for the arm muscles \[14\]. Women were asked to exercise continuously for 60 mins, by performing the arm exercises by repeating the session, and were instructed to exercise at moderate intensity .